A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
NCT05808764
Recruiting
This study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at first dose.
Gender:
ALL
Ages:
19 days and below
Trial Updated:
05/19/2025
Locations: Ann and Robert H. Lurie Children Hospital of Chicago, Chicago, Illinois +12 locations
Conditions: Muscular Atrophy, Spinal
Register for Updates
Assessing the Use of MY-RIDE, a Just-in-time Adaptive Intervention, to Improve HIV Prevention and Substance Use in Youth Experiencing Homelessness
NCT06074354
Recruiting
The purpose of this study is to determine whether Motivating Youth to Reduce Infections, Disconnections, and Emotion dysregulation (MY-RIDE) decreases substance use , to determine whether MY-RIDE increases human immunodeficiency virus (HIV) prevention strategies and to evaluate MY-RIDE effects on willingness to take Pre-Exposure Prophylaxis (PrEP), stress, substance use urge, and use of mental health and substance use services when compared to attention control youth
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
05/19/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: HIV Infections
Register for Updates
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
NCT06333262
Recruiting
This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: New England Cancer Specialists, Scarborough, Maine +3 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Avalus Ultra Post-Approval Study (PAS)
NCT06506903
Recruiting
The purpose of this study is to characterize the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients with aortic valve disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Hartford Hospital, Hartford, Connecticut +11 locations
Conditions: Aortic Valve Disease
Register for Updates
Effectiveness of Central Oncology Navigation and the Use of an ORN
NCT06618274
Recruiting
This health services interventional study investigates the effectiveness of central oncology navigation (SOC ) alone and central oncology navigation with a new role called an "oncology research navigator (ORN)" who is embedded in central oncology navigation cancer care delivery. This study will examine two patient cohorts: Cohort 1 will enroll patients with new cancer appointments within genitourinary (GU) or thoracic cancers. These clinics have not yet implemented the central navigation program... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Cancer, Malignant Tumor
Register for Updates
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
NCT06746883
Recruiting
The goal of this observational study is to evaluate the safety of sulbactam-durlobactam, as well as the risk of hypersensitivity reactions (including anaphylaxis) in participants with Acinetobacter baumannii-calcoaceticus complex infection. Participants will be followed for approximately 28 days in order to collect safety and reaction data.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Ochsner LSU Health Science Center Shreveport, Shreveport, Louisiana +1 locations
Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Register for Updates
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080
Recruiting
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME). In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be ent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Scottsdale, AZ, Scottsdale, Arizona +82 locations
Conditions: Diabetic Macular Edema (DME)
Register for Updates
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
NCT01608152
Recruiting
This trial collects feedback from patients to develop a video game in improving the outcomes in stem cell transplant survivors. A video game may help to improve health behaviors for leukemia or lymphoma patients after stem cell transplant.
Gender:
ALL
Ages:
Between 15 years and 39 years
Trial Updated:
05/19/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Leukemia, Lymphoma
Register for Updates
Immunization With BCG Vaccine to Prevent Tuberculosis Infection
NCT04453293
Recruiting
The purpose of this research is to find out if a single dose of pre-travel vaccination with BCG can lessen tuberculosis (TB) infection by producing an immune response when given to adults traveling to countries with a high burden of TB. BCG will be compared with a placebo (an inactive vaccine). BCG (Japan) is used globally but is not approved for use in the United States, therefore it is considered experimental. Participants choosing to take part in this research study, will be randomly assigned... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/19/2025
Locations: Yale University School of Medicine, New Haven, Connecticut +6 locations
Conditions: Tuberculosis Infection
Register for Updates
Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool
NCT05047224
Recruiting
The investigators propose to evaluate the use of a telemedicine tool, the TELE-ASD-PEDS (TAP), that is designed to assess for autism spectrum disorder (ASD) symptoms in toddlers. The TAP was developed at VUMC by a team of clinical psychologists with expertise in the early identification of ASD. The TAP has been studied in controlled laboratory settings, with high levels of family and clinician satisfaction, as well as excellent agreement with blinded comprehensive ASD evaluation. The TAP has als... Read More
Gender:
ALL
Ages:
Between 18 months and 42 months
Trial Updated:
05/19/2025
Locations: UC Davis MIND Institute, Sacramento, California
Conditions: Autism Spectrum Disorder
Register for Updates
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
NCT05472792
Recruiting
The aim of this prospective study is to investigate quality of life and oncologic outcomes in low-risk elderly breast cancer patients randomized to adjuvant therapy with accelerated partial breast irradiation (APBI) alone or endocrine therapy alone after lumpectomy. The study population will include women age 65 years and older with low-risk tumor characteristics (tumor size \<2cm, grade 1-2, node-negative). APBI will consist of 5 fractions of radiation therapy delivered every other day to the l... Read More
Gender:
FEMALE
Ages:
65 years and above
Trial Updated:
05/19/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Breast Cancer, Quality of Life
Register for Updates
COPEWeb Training for Providers
NCT05812131
Recruiting
PTSD and substance use disorders (SUD) are two of the most common and debilitating mental health conditions afflicting military Veterans. PTSD and SUD frequently co-occur and are associated with poorer treatment outcomes. The investigators' team developed a trauma-focused intervention, Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE), which is identified by the VA as a gold standard of behavioral healthcare. However, a critical barrier to ensuring that Vet... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina
Conditions: PTSD, Substance Use Disorders
Register for Updates